Biogen BIIB PLEGRIDY — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Biogen in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Biogen’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Biogen's plegridy — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Biogen's PLEGRIDY — total revenue?
- Biogen (BIIB) reported PLEGRIDY — total revenue of $64.3M in Q1 2026.
- How has Biogen's PLEGRIDY — total revenue changed year-over-year?
- Biogen's PLEGRIDY — total revenue increased by 8.1% year-over-year, from $59.5M to $64.3M.
- What is the long-term trend for Biogen's PLEGRIDY — total revenue?
- Over 4 years (2021 to 2025), Biogen's PLEGRIDY — total revenue has grown at a -8.5% compound annual growth rate (CAGR), from $357.4M to $250.1M.
- What does PLEGRIDY — total revenue mean?
- This metric represents the total gross revenue generated from the sale of a specific pharmaceutical product within the company's multiple sclerosis portfolio. It reflects the market demand, pricing power, and competitive positioning of this specific therapy as it moves through its product lifecycle. Tracking this revenue stream is essential for evaluating the contribution of individual assets to the company's overall top-line performance and therapeutic franchise stability.